FIELD: medicine; immunology.
SUBSTANCE: group of inventions can be used to determine total periostin in a biological sample obtained from an asthmatic patient. For this purpose, in order to stratify/classify asthmatic patients on sensitive and non-therapeutic therapeutic pathway inhibitor TH2 kit contains an antibody, which binds to common periostin, and an insert into the package, wherein the common periosteum contains human periostin isoforms 1, 2, 3 and 4. Group of inventions also relates to a kit for measuring total periostin in an asthmatic patient, to determine whether an asthmatic patient is positive by eosinophilic inflammation (EIP).
EFFECT: use of the given group of inventions enables to diagnose the EIP status in the patient by the common analysis of periostin, as well as to determine patient's sensitivity to therapeutic treatment with TH2 pathway inhibitor.
64 cl, 8 ex, 14 tbl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA | 2009 |
|
RU2607569C2 |
| USE OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS | 2017 |
|
RU2752785C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES | 2019 |
|
RU2795180C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATIC PATIENTS USING BENRALIZUMAB | 2014 |
|
RU2703568C2 |
| ANTIBODY FORMULATIONS | 2012 |
|
RU2665810C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING OF BENRALIZUMAB | 2014 |
|
RU2676333C2 |
